TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer

Zhang, Guonan; Liu, Hong; Huang, Jianming; Zhao, Jing-sha; Li, Chao; Mi, Kun; Zhu, Yi; Cheng, Jing; Xiao, Zhengguo

doi:10.1016/j.ygyno.2014.01.028

Cited by 33 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These molecular differences may deliver the basis for individualized therapy approaches in future. Other investigators tried to evaluate molecular biomarkers and gene-profiling to predict platinum resistance [38] and residual tumor status after debulking surgery [39,40]. However, none of these findings focus exclusively on stage IV EOC.…”

Section: Tumor Biologymentioning

confidence: 99%

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

Ataseven

Chiva

Harter

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Tumor Biologymentioning

confidence: 99%

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

Ataseven

Chiva

Harter

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

“…NACT can decrease tumor volume, thereby allowing for a less traumatic surgery and a higher R0 resection rate [24]. However, this treatment exposes a high tumor burden to chemotherapeutic drugs, which results in a selection of resistant tumor clones [29,30]. Even among HGSC patients with BRCA1-heterozygous tumors that are supersensitive to DNA-damaging drugs and poly (ADP-ribose) polymerase (PARP) inhibitors, the utility of NACT is observed to facilitate the expansion of pre-existing BRCA1pro cient tumor clones [31].…”

Section: Discussionmentioning

confidence: 99%

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

Liang

Lijuan

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To investigate whether CA125 normalization following neoadjuvant chemotherapy (NACT) can complement the chemotherapy response system (CRS) in the prognostication of patients with tubo-ovarian high-grade serous carcinoma (HGSC).Methods: In total, 106 HGSC patients who received NACT followed by interval debulking surgery (IDS) for FIGO stage IIIC-IV disease were included, and their clinical data were retrospectively reviewed. The primary endpoint was progression-free survival (PFS). Cox regression analysis was performed to identify predictors of PFS.Results: Following NACT, CRS3 was noted in 24 patients (22.6%), and CA125 normalization (≤ 35 U/ml) was noted in 54 patients (50.9%). Both CRS3 and CA125 normalization were identified as independent prognosticators of PFS. Combining these two factors, we stratified the 106 patients into three groups with different risks of recurrence: low-risk group (CRS3 + post-NACT CA125≤ 35 U/ml; n = 17, 16.0%), intermediate-risk group (CRS3 + post-NACT CA125 > 35 U/ml; n = 7, 6.6%) and high-risk group (CRS1-2; n= 82, 77.4%). The differences in PFS between the three groups were significant (log-rank test, P < 0.0001). In Cox regression analyses, the new stratification method was found to have an independent prognostic effect.Conclusion: Both the CRS system and the normalization of CA125 following NACT could reliably predict the risk of recurrence following primary treatment. The combination of the two factors refined the prognostic stratification of HGSC patients who were treated with NACT and IDS.

show abstract

“…Furthermore, many other factors affect PFS and OS, including the histological type, stage, residual tumor size, and age. Chemosensitivity is also influenced by many factors 24, 25, 26, 27, 28. In the patients with epithelial OC, a sensitivity to both paclitaxel and platinum affected their response to chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Chemosensitivity is also influenced by many factors. [24][25][26][27][28] In the patients with epithelial OC, a sensitivity to both paclitaxel and platinum affected their response to chemotherapy. Therefore, the current authors investigated the relationship between paclitaxel use and Tau protein expression in the epithelial OC cells.…”

Section: Discussionmentioning

confidence: 99%

Functional role of the Tau protein in epithelial ovarian cancer cells

Yamauchi

Kobayashi

Oikiri

et al. 2017

Reprod Medicine & Biology

View full text Add to dashboard Cite

AimThe microtubule‐associated Tau protein is a marker of paclitaxel sensitivity in ovarian cancer. The aim of the present study was to elucidate the function of the Tau protein in epithelial ovarian cancer.MethodsThe correlation between Tau protein expression and the response to paclitaxel by using several ovarian cancer cell lines was investigated.ResultsA Western blot showed that the expression level of the Tau protein was the highest in the TOV112D cells. A cell‐counting kit showed that the proliferation rates were more inhibited in the cells with down‐regulated Tau protein than in the control cells, both with and without paclitaxel treatment. The proliferation rates of the control cells and the TOV112D cells also were compared with Tau protein overexpression. The level of cell proliferation was more inhibited in the cells that overexpressed the Tau protein, compared to the control cells, both with and without paclitaxel treatment. It was shown that both the down‐regulation and the overexpression of the Tau protein were related to the inhibition of TOV112D cell proliferation. Early and late apoptosis of the TOV112D cells that were transfected with Tau cDNA plasmid construct or Tau small interfering RNA significantly increased.ConclusionThese findings suggest that the molecular targeting of the Tau protein could be a potential treatment for ovarian cancer.

show abstract

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer

Cited by 33 publications

References 30 publications

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

Functional role of the Tau protein in epithelial ovarian cancer cells

Contact Info

Product

Resources

About